NCT03742349 - Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2019

Primary Completion Date

February 6, 2023

Study Completion Date

February 6, 2023

Conditions

Triple Negative Breast Cancer (TNBC)

Interventions

BIOLOGICAL

spartalizumab

LIVI (Liquid in vial) Concentrate for Solution for infusion

BIOLOGICAL

LAG525

LAG525 LIVI (Liquid in vial) Concentrate for Solution for infusion

DRUG

NIR178

Capsule

DRUG

capmatinib

Tablet

BIOLOGICAL

MCS110

LIVI (Liquid in vial) Concentrate for Solution for infusion

BIOLOGICAL

canakinumab

LIVI (Liquid in vial) Solution for injection

Trial Locations (13)

2145

Novartis Investigative Site, Westmead

10032

Columbia University Medical Center- New York Presbyterian Columbia, New York

20133

Novartis Investigative Site, Milan

20141

Novartis Investigative Site, Milan

37203

Sarah Cannon Research Institute Sarah Cannon Research, Nashville

46010

Novartis Investigative Site, Valencia

119074

Novartis Investigative Site, Singapore

169610

Novartis Investigative Site, Singapore

6423906

Novartis Investigative Site, Tel Aviv

Unknown

Novartis Investigative Site, Shatin, New Territories

277 8577

Novartis Investigative Site, Kashiwa

1066 CX

Novartis Investigative Site, Amsterdam

08035

Novartis Investigative Site, Barcelona